Vitamin B 12 deficiency and hyperhomocysteinemia are common in tropical developing countries. In prevalence study, among Indian population by Yajnik and colleagues, 67% of men had low vitamin B 12 concentration and 58% had hyperhomocysteinemia [1] . Here, we report two patients with vitamin B 12 deficiency presented with symptoms of schizophrenia and required very high doses of antipsychotic medication surprisingly without any anticipated extra pyramidal side effects. The initial requirement of high dose of antipsychotic medication significantly came down after adding parenteral cobalamin supplementation.
Introduction
Vitamin B 12 deficiency and hyperhomocysteinemia play important role in resistant schizophrenia. Low serum B12 level has been reported in resistant schizophrenia in literature [1] . Vitamin supplementation could provide therapeutic benefits through separate mechanisms of action than current medication regimens, which focus largely on monoamine and histamine signalling. The research indicates that taken in high doses, B vitamins-such as B-6, B-8, and B-12-can significantly reduce schizophrenia symptoms. Additionally, a combined dose of several vitamins was shown to have the same beneficial effect. However, low doses of the vitamins were revealed to be ineffective. 
Case I
A 24 year old male, presented with an 8 month history suggestive of schizophrenia with normal cognitive and neurological functions. He was started on oral risperidone and the dose was gradually increased to 12 mg/day, due to poor response to treatment however no extra pyramidal side effects were noted. As the MCV was 98.4 [75 -96 fl] he was evaluated for B 12 and folic acid deficiency. Serum B 12 was 159.5 pgm/ml (normal range: 220 -900 pgm/ml), folic acid was 4.08 ng/ml (normal range: 3 -17 ngm/ml) and homocysteine was 58.5 µM/L (normal range: 4.3 -9.9 μM/L), confirming the possibility of vitamin B 12 deficiency. Renal and hepatic indices were normal. Mr. A was started on a course of intramuscular vitamin B 12 injections. After two months of treatment he developed extrapyramidal side effects and the dose of risperidone was reduced gradually to 6 mg daily without any worsening of psychotic symptoms. His homocysteine level has come down to normal limit at that time. He remained asymptomatic and was functioning well at 6 months follow up.
Case II
Mr. B, a 28 year old male, presented with a 2 year history suggestive of schizophrenia and his symptoms were uncontrolled over the preceding six months. At presentation he was on high doses of two typical antipsychotics (chlorpromazine and trifluoperazine) equivalent to 1400 mg daily dose of chlorpromazine with no manifestions of extrapyramidal symptoms. On examination, he had pallor, glossitis and angular stomatitis with normal cognitive and neurological functions. 
Discussion
The role of one carbon metabolism in neuropsychiatric disorders is reviewed by Smythies et al. and Cohen et al. [2] [3] . While there are many reports of schizophrenia being associated with vitamin B 12 deficiency, we would like to highlight two issues relevant to the above mentioned case scenarios [4] . 1) Need for high dose antipsychotic therapy in the acute phase of treatment and lack of extrapyramidal side effects in this group of patients.
2) Evaluation for B 12 and folate deficiency should be included in the assessment for treatment resistant psychosis.
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OALib Journal (Figure 1 ). In Vitamin B 12 or folic acid deficiency states this remethylation will be reduced, which in turn reduce the synthesis of SAM and results in decreased synthesis of Noradreranaline or accumulation of Dopamine [6] .
In developing countries, underlying B 12 deficiency should be considered in all the patients who are not responding to antipsychotic medications and before labelling them as treatment resistance or commencing on 2 nd line therapies like clozapine. It is advisable to do B 12 level during the initial evaluation because psychosis can precede anaemia. Homocystine assay is also to be considered in selected cases [7] in a view of early initiation of cobalamin supplementation.
Vitamin B 12 deficiency and hyperhomocysteinemia was an etiological factor in our cases. Vitamin B 12 therapy had a significant outcome in our cases. Low serum B 12 levels have been reported in resistant schizophrenia [1] and Vitamin B 12 therapy had good outcome in literature [5] .
The informed consent was obtained from the patients to report this case in this journal.
